The FDA Approves One New Hyperkalemia Drug, Requires Drug Interaction Study for AnotherAschenbrenner, Diane S. MA, RNAJN, American Journal of Nursing: February 2016 - Volume 116 - Issue 2 - p 23 doi: 10.1097/01.NAJ.0000480492.33351.de Drug Watch Buy Abstract Author InformationAuthors Article MetricsMetrics Patiromer (Veltassa), an oral suspension that binds potassium in the gastrointestinal tract, has been approved to treat hyperkalemia. Patiromer binds to many medicines, potentially decreasing their effectiveness. Thus nurses should instruct patients to take patiromer at least six hours before or after taking other medications. Because significant interactions between patiromer and sodium polystyrene sulfonate (Kayexalate) are possible, the Food and Drug Administration has required that a drug interaction study be completed by Kayexalate's manufacturer. Diane S. Aschenbrenner was previously the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: firstname.lastname@example.org. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.